Envista (NYSE:NVST) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Envista (NYSE:NVST) from a buy rating to a strong-buy rating in a report released on Monday.

Several other equities research analysts have also issued reports on the stock. Evercore ISI restated an “outperform” rating on shares of Envista in a report on Friday, October 31st. Robert W. Baird set a $27.00 price objective on shares of Envista in a research report on Friday, October 31st. JPMorgan Chase & Co. raised their price objective on shares of Envista from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Tuesday, December 16th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Envista in a research note on Monday, December 29th. Finally, Stifel Nicolaus set a $25.00 price target on Envista in a report on Thursday, October 30th. Five investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Envista has an average rating of “Hold” and a consensus price target of $22.17.

Envista Price Performance

NYSE:NVST opened at $24.09 on Monday. The firm has a market capitalization of $3.96 billion, a price-to-earnings ratio of 267.64, a PEG ratio of 1.07 and a beta of 0.99. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.37 and a quick ratio of 2.02. The business has a 50 day simple moving average of $22.25 and a 200-day simple moving average of $21.01. Envista has a 1 year low of $14.22 and a 1 year high of $25.41.

Envista (NYSE:NVST) last released its quarterly earnings results on Wednesday, October 29th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.05. The company had revenue of $669.90 million for the quarter, compared to analyst estimates of $639.49 million. Envista had a return on equity of 5.90% and a net margin of 0.58%.Envista’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.12 EPS. Equities analysts forecast that Envista will post 1 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of NVST. GAMMA Investing LLC raised its position in Envista by 34.3% during the 3rd quarter. GAMMA Investing LLC now owns 2,498 shares of the company’s stock valued at $51,000 after purchasing an additional 638 shares in the last quarter. Assetmark Inc. increased its stake in shares of Envista by 1.4% during the fourth quarter. Assetmark Inc. now owns 46,273 shares of the company’s stock valued at $1,005,000 after buying an additional 659 shares during the period. Claret Asset Management Corp increased its stake in shares of Envista by 6.5% during the second quarter. Claret Asset Management Corp now owns 11,827 shares of the company’s stock valued at $231,000 after buying an additional 724 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Envista by 35.3% in the third quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,041 shares of the company’s stock valued at $62,000 after acquiring an additional 793 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its stake in Envista by 317.6% in the third quarter. Farther Finance Advisors LLC now owns 1,349 shares of the company’s stock worth $27,000 after acquiring an additional 1,026 shares during the period.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.